Drug Trial Radar · NCT05803902
An Evaluation of 9MW1911 Injection in Healthy Subjects
Last checked: Nov 20, 2026Latest source record: Dec 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
48
Actual
Start
Dec 15, 2021
Primary completion
Mar 6, 2023
Study completion Mar 6, 2023
Sponsor
- Lead sponsor
- Mabwell (Shanghai) Bioscience Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Apr 7, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study is a randomized, double-blind, dose-escalating phase I clinical study to evaluate the safety, tolerability and pharmacokinetics of 9MW1911 injection in healthy subjects.
Conditions
- Asthma
- COPD
- Atopic Dermatitis
Interventions
Experimental drug 9MW1911Drug
Experimental drug administered with IV infusion
PlaceboDrug
Placebo administered with IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Adverse Event(including serious adverse event)Time frame: Day0-Day113
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking Union Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.